Poster Session One
Therapies – clinical testing
A179 – A201
- A179: A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12, ISRCTN83176944)
- A180: Is chemotherapy re-challenge worthwhile in patients with recurrent gastroesophageal cancer?
- A181: Capturing expert opinion at an international meeting (IM) to define what constitutes a practice changing difference between randomised arms in an NCRN clinical trial featuring de-escalation of treatment in Hodgkin lymphoma (HL)
- A182: The role of upper gastrointestinal multidisciplinary teams in recruiting patients into randomised controlled trials
- A183: A phase I dose escalation study of an irreversible EGFR/HER2 dual kinase inhibitor in combination with weekly paclitaxel
- A184: Abstract withdrawn
- A185: The NUT study: the effect of dietetic and oral nutritional interventions on survival and quality of life in patients with weight loss undergoing palliative chemotherapy for gastrointestinal (GI) or lung malignancy: a randomised controlled trial
- A186: Interim results of a randomised controlled trial into the safety and efficacy of ALA versus photobarr PDT for high grade dysplasia in Barrett’s oesophagus
- A187: Impact of margin status on survival following pancreatoduodenectomy for cancer – the Leeds Pathology Protocol (LEEPP)
- A188: Trastuzumab cardiotoxicity and cardiac monitoring in adjuvant breast cancer patients – the Merseyside and Cheshire Cancer Network experience
- A189: Toxicity results from the chemotherapy versus no chemotherapy comparison within BC2001 - a phase III randomised trial of standard versus reduced volume radiotherapy with or without synchronous chemotherapy in muscle invasive bladder cancer
- A190: A Phase II study of intravenous CNTO328 in patients with recurrent epithelial ovarian cancer
- A191: Zoledronic acid (ZOL) improves survival in patients with metastatic bone disease and high bone turnover: a meta-analysis of placebo controlled trials
- A192: Treatment with weekly 1-hour infusion of paclitaxel in metastatic breast cancer
- A193: Phase I trial of an oral c-Met inhibitor ARQ197, which inhibits tumour c-Met and FAK phosphorylation and has reached maximum tolerated dose(MTD) in a twice daily (bd) dosing schedule
- A194: Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma
- A195: Validation of a serum Rituximab assay for use in clinical trials
- A196: A phase I trial of the heat-shock protein 90 (HSP90) inhibitor alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours
- A197: Improving survival for squamous cell carcinoma of the oral cavity
- A198: Sunitinib in patients with metastatic renal cell carcinoma
- A199: The effect of omega-3 fatty acids (O-3FA) on antioxidant status, human leukocyte antigen (HLA)-DR expression on leukocytes and clinical outcome in oesophago-gastric cancer surgery (OGCS)
- A200: Optimal capecitabine regime for use within combination chemotherapy for gastroesophageal cancer
- A201: Survival, tolerability of treatment and prognostic factors in elderly patients receiving chemotherapy for advanced pancreatic cancer: a retrospective analysis
